Status: Recruiting
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 16 Years or Older with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)
Participants needed: 30
Trial details
Phase: Phase 2Age: 16+Biological sex: AllType: InterventionalSponsor: Akebia TherapeuticsUpdated: Aug 4, 2026Locations: 2
Eligibility criteria
Male or female participants aged ≥16 years. [+9]
Rapidly progressive glomerulonephritis defined as a 50% decline in eGFR within 1... [+11]